Clinical data | |
---|---|
Trade names | Lotronex |
AHFS/Drugs.com | Monograph |
MedlinePlus | a601230 |
Routes of administration | Oral (tablets) |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 50–60% |
Protein binding | 82% |
Metabolism | Hepatic (including CYP2C9, CYP3A4 and CYP1A2) |
Elimination half-life | 1.5–1.7 hours |
Excretion | Renal 73%, faecal 24% |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C17H18N4O |
Molar mass | 294.358 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Alosetron, sold under the brand name Lotronex among others, is a 5-HT3 antagonist used for the management of severe diarrhea-predominant irritable bowel syndrome (IBS) in females only.
It was patented in 1987 and approved for medical use in 2002.[2] It is currently marketed by Prometheus Laboratories Inc. (San Diego). Alosetron was withdrawn from the market in 2000 owing to the occurrence of serious life-threatening gastrointestinal adverse effects, but was reintroduced in 2002 with availability and use restricted.